EOLS – Evolus, Inc.
Evolus, Inc. Common StockEOLS
$6.95Name : Evolus, Inc. Common Stock
Sector : Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Mark. Cap: $450,173,408.00
EPSttm : -0.9
Evolus, Inc. Common Stock
$6.95
3.81%$0.275Float Short %
26.05
Margin Of Safety %
Put/Call OI Ratio
0.03
EPS Next Q Diff
0.21
EPS Last/This Y
0.46
EPS This/Next Y
0.59
Price
7.2
Target Price
18.67
Analyst Recom
1.29
Performance Q
7.92
Relative Volume
1.51
Beta
0.85
Ticker: EOLS
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-10-20 | EOLS | 6.69 | 0.03 | 0.00 | 6831 |
| 2025-10-21 | EOLS | 6.8 | 0.03 | 0.10 | 6866 |
| 2025-10-22 | EOLS | 6.82 | 0.03 | 6.25 | 6961 |
| 2025-10-23 | EOLS | 6.74 | 0.04 | 0.00 | 6985 |
| 2025-10-24 | EOLS | 6.78 | 0.04 | 0.15 | 6985 |
| 2025-10-27 | EOLS | 7.22 | 0.04 | 0.03 | 7031 |
| 2025-10-28 | EOLS | 7.05 | 0.04 | 0.00 | 7120 |
| 2025-10-29 | EOLS | 6.87 | 0.04 | 0.00 | 7135 |
| 2025-10-30 | EOLS | 6.7 | 0.04 | 0.00 | 7071 |
| 2025-10-31 | EOLS | 6.46 | 0.04 | 0.35 | 7059 |
| 2025-11-03 | EOLS | 6.38 | 0.04 | 0.00 | 7117 |
| 2025-11-04 | EOLS | 6.41 | 0.04 | 0.00 | 7160 |
| 2025-11-05 | EOLS | 6.82 | 0.03 | 0.00 | 8382 |
| 2025-11-06 | EOLS | 7.2 | 0.02 | 0.23 | 19573 |
| 2025-11-07 | EOLS | 6.57 | 0.03 | 0.13 | 19321 |
| 2025-11-10 | EOLS | 7.05 | 0.03 | 0.41 | 19570 |
| 2025-11-11 | EOLS | 6.97 | 0.03 | 0.00 | 19558 |
| 2025-11-12 | EOLS | 7.29 | 0.03 | 0.95 | 19550 |
| 2025-11-13 | EOLS | 7.36 | 0.03 | 0.01 | 19555 |
| 2025-11-14 | EOLS | 7.22 | 0.03 | 0.03 | 19651 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-10-20 | EOLS | 6.69 | -0.4 | 63.1 | -0.56 |
| 2025-10-21 | EOLS | 6.80 | -0.4 | 62.6 | -0.56 |
| 2025-10-22 | EOLS | 6.82 | -0.4 | 62.4 | -0.56 |
| 2025-10-23 | EOLS | 6.74 | -0.4 | 62.1 | -0.56 |
| 2025-10-24 | EOLS | 6.77 | -0.4 | 62.4 | -0.56 |
| 2025-10-27 | EOLS | 7.21 | -0.4 | 63.5 | -0.56 |
| 2025-10-28 | EOLS | 7.04 | -0.4 | 52.2 | -0.56 |
| 2025-10-29 | EOLS | 6.87 | -0.4 | 52.2 | -0.56 |
| 2025-10-30 | EOLS | 6.72 | -0.4 | 52.2 | -0.56 |
| 2025-10-31 | EOLS | 6.46 | -0.4 | 52.1 | -0.56 |
| 2025-11-03 | EOLS | 6.38 | -0.4 | 52.3 | -0.56 |
| 2025-11-04 | EOLS | 6.42 | -0.4 | 52.5 | -0.56 |
| 2025-11-05 | EOLS | 6.82 | -0.4 | 53.1 | -0.56 |
| 2025-11-06 | EOLS | 7.20 | -0.4 | 53.0 | -0.56 |
| 2025-11-07 | EOLS | 6.56 | -1.4 | 48.4 | -0.57 |
| 2025-11-10 | EOLS | 7.05 | 331.7 | 50.4 | -0.57 |
| 2025-11-11 | EOLS | 6.99 | 331.7 | 36.6 | -0.35 |
| 2025-11-12 | EOLS | 7.30 | 331.7 | 36.5 | -0.35 |
| 2025-11-13 | EOLS | 7.36 | 331.7 | 36.5 | -0.35 |
| 2025-11-14 | EOLS | 7.20 | 403.6 | 36.6 | -0.35 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-10-20 | EOLS | -0.78 | 4.74 | 24.98 |
| 2025-10-21 | EOLS | -0.78 | 4.74 | 24.98 |
| 2025-10-22 | EOLS | -0.78 | 4.74 | 24.98 |
| 2025-10-23 | EOLS | -0.78 | 4.74 | 24.98 |
| 2025-10-24 | EOLS | -0.78 | 4.74 | 24.98 |
| 2025-10-27 | EOLS | -0.78 | 4.75 | 26.09 |
| 2025-10-28 | EOLS | -0.78 | 4.75 | 26.09 |
| 2025-10-29 | EOLS | -0.78 | 4.75 | 26.09 |
| 2025-10-30 | EOLS | -0.78 | 4.75 | 26.09 |
| 2025-10-31 | EOLS | -0.78 | 4.75 | 26.09 |
| 2025-11-03 | EOLS | -0.78 | 4.59 | 26.09 |
| 2025-11-04 | EOLS | -0.78 | 4.59 | 26.09 |
| 2025-11-05 | EOLS | -0.78 | 4.59 | 26.09 |
| 2025-11-06 | EOLS | -0.78 | 4.59 | 26.09 |
| 2025-11-07 | EOLS | -0.78 | 4.59 | 26.09 |
| 2025-11-10 | EOLS | -0.78 | 4.81 | 26.04 |
| 2025-11-11 | EOLS | -0.78 | 4.81 | 26.04 |
| 2025-11-12 | EOLS | -0.78 | 4.81 | 26.05 |
| 2025-11-13 | EOLS | -0.78 | 4.81 | 26.05 |
| 2025-11-14 | EOLS | -0.78 | 4.81 | 26.05 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.2
Avg. EPS Est. Current Quarter
0.07
Avg. EPS Est. Next Quarter
0.01
Insider Transactions
-0.78
Institutional Transactions
4.81
Beta
0.85
Average Sales Estimate Current Quarter
91
Average Sales Estimate Next Quarter
80
Fair Value
Quality Score
30
Growth Score
52
Sentiment Score
47
Actual DrawDown %
59.6
Max Drawdown 5-Year %
-68.4
Target Price
18.67
P/E
Forward P/E
34.15
PEG
P/S
1.64
P/B
P/Free Cash Flow
EPS
-0.91
Average EPS Est. Cur. Y
-0.35
EPS Next Y. (Est.)
0.24
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-20.49
Relative Volume
1.51
Return on Equity vs Sector %
176.7
Return on Equity vs Industry %
196.4
EPS 1 7Days Diff
0.2
EPS 1 30Days Diff
0.21
EBIT Estimation
36.6
Evolus, Inc. Common StockSector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 329
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
stock quote shares EOLS – Evolus, Inc. Stock Price stock today
news today EOLS – Evolus, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch EOLS – Evolus, Inc. yahoo finance google finance
stock history EOLS – Evolus, Inc. invest stock market
stock prices EOLS premarket after hours
ticker EOLS fair value insiders trading